A Multicenter, Open-Label, Single-Arm, Phase 1 Dose-Escalation and Phase 2 Dose-Expansion Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of FCN-159 in Adults with Neurofibromatosis Type 1.
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
Neurofibromatosis
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要